Mini transplant shows promise for blood cancers – but trial ended early
NCT ID NCT01135329
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a reduced-intensity bone marrow transplant, or 'mini transplant,' for people with blood cancers like lymphoma and leukemia. The transplant used marrow from a relative and was combined with chemotherapy drugs to help the donor cells take hold. Only 15 people took part before the trial was stopped early. The main goal was to see how well the donor cells engrafted, but the small size and early end mean we can't draw firm conclusions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
bone marrow transplant with chemotherapy drugs (fludarabine, busulfan, cyclophosphamide) and immune-suppressing drugs (mycophenolate mofetil, tacrolimus)
What this could lead to
If successful, this approach could offer a less intense transplant option for blood cancer patients, potentially reducing side effects while still controlling the disease.
What could go wrong
This was a small, early-phase trial that ended early, so results are limited. The transplant still carries risks like graft-versus-host disease and infection, and it may not work for everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Sydney Kimmel Comprehensive Cancer Center
Baltimore, Maryland, 21231, United States